Ozone, Macrophage Efferocytosis, and Neuropathic Pain

Study Background and Research Question

Neuropathic pain arises from injury or disease affecting the somatosensory system and is commonly accompanied by spontaneous pain, abnormal sensory processing, hyperalgesia, and allodynia. Although first-line treatments include antidepressants and gabapentinoids, tolerability, incomplete efficacy, dependence, and other limitations continue to motivate the search for mechanism-based interventions. The reference study, published in 2024 in Frontiers in Immunology, addresses this problem by examining whether defective removal of apoptotic cells contributes to persistent neuroinflammation and pain.

The authors focused on efferocytosis, the process by which phagocytes recognize, engulf, and process dying cells. After peripheral nerve injury, apoptotic-cell accumulation and the release of damage-associated signals may sustain immune activation. Macrophages can limit this process through efficient efferocytosis, but the relevant regulatory pathway in neuropathic pain had not been defined in detail. The central question was therefore whether ozone could enhance macrophage clearance of apoptotic cells and, if so, whether this effect depended on the AMPK/Gas6–MerTK/SOCS3 axis. The study design and findings are reported in the reference article.

Key Innovation from the Reference Study

The main innovation is conceptual as well as mechanistic. Rather than treating ozone only as a broadly acting analgesic or anti-inflammatory intervention, the authors place macrophage efferocytosis at the center of the response. Their model proposes that ozone activates AMP-activated protein kinase, increases Gas6 production, stimulates the MerTK phagocytic receptor, and thereby improves the uptake of apoptotic neutrophils. Enhanced clearance is associated with increased SOCS3 expression and reduced production of IL-1β, IL-6, and TNF-α.

This framework is important because it links three levels of biology: cellular housekeeping, innate immune signaling, and pain behavior. It also distinguishes Gas6 from Protein S, reporting that ozone increased Gas6 but did not produce the same change in Protein S. That selectivity narrows the proposed mechanism and suggests that the Gas6–MerTK branch is more relevant than a nonspecific increase in all MerTK ligands. The study consequently reframes efferocytosis as a potentially actionable component of neuroinflammatory pain biology rather than merely a downstream consequence of tissue damage.

Methods and Experimental Design Insights

The in vivo experiments used mice subjected to chronic constriction injury, a peripheral nerve injury model that produces mechanical hypersensitivity. Ozone was administered at different study-defined doses, allowing the investigators to compare behavioral and inflammatory responses rather than relying on a single exposure condition. Mechanical sensitivity served as the principal functional readout for pain-related behavior.

To examine macrophage function more directly, the investigators used bone marrow-derived macrophages, or BMDMs, in vitro. These cells were exposed to ozone and then assessed for their ability to phagocytose apoptotic neutrophils. This two-part design was useful: the animal experiments connected ozone to pain behavior, whereas the BMDM assay tested whether macrophage clearance capacity could be directly altered by the treatment.

The mechanistic experiments combined expression analysis with pharmacological inhibition. AMPK involvement was tested using compound C, referred to in the study as CC, while MerTK dependence was examined with UNC2541. The authors also measured pathway-associated molecules, including AMPK activation, Gas6, Protein S, MerTK, and SOCS3, together with inflammatory cytokines. This progression from behavior to cell function, pathway markers, and inhibitor reversal strengthens the causal interpretation, although pharmacological inhibitors should still be interpreted with awareness of potential off-target effects.

Protocol Parameters

• Neuropathic pain model: The reference study used chronic constriction injury in mice and evaluated treatment effects through mechanical hypersensitivity testing.
• Ozone comparison: The investigators examined 15 mg, 30 mg, and 45 mg ozone conditions; the 30 mg condition was reported as producing a significant improvement in mechanical hypersensitivity in the study model.
• Macrophage assay: BMDMs were tested for uptake of apoptotic neutrophils after ozone treatment, providing a cellular efferocytosis endpoint separate from animal behavior.
• Pathway blockade: Compound C was used to interrogate AMPK dependence, and UNC2541 was used to inhibit MerTK signaling. These are literature-backed study parameters rather than universal dosing recommendations.
• Workflow interpretation: Replication should preserve the original study's treatment timing, injury procedure, inhibitor schedule, and behavioral-testing conditions rather than inferring them from the dose comparison alone.

Core Findings and Why They Matter

The clearest behavioral result was that the 30 mg ozone condition significantly reduced mechanical hypersensitivity in CCI mice. This dose-response comparison is informative because it indicates that the reported benefit was not presented as an automatic consequence of increasing ozone exposure. The result instead supports the need to define an effective experimental window for subsequent mechanistic work.

At the cellular level, ozone increased the phagocytic activity of BMDMs toward apoptotic neutrophils. In the proposed signaling sequence, AMPK activation was followed by increased Gas6, MerTK activation, and enhanced efferocytosis. SOCS3 expression also increased, whereas inflammatory mediators including IL-1β, IL-6, and TNF-α decreased. Together, these observations support a model in which improved removal of dying cells is associated with a less inflammatory macrophage response.

The inhibitor experiments are particularly meaningful. The analgesic effect of ozone was abolished when AMPK was inhibited by compound C or when MerTK was blocked by UNC2541. These findings do not prove that every step is exclusively dependent on these targets, but they do provide pharmacological evidence that both AMPK activity and MerTK signaling are functionally important for the observed phenotype. The paper therefore advances beyond correlation between ozone exposure and reduced pain, proposing a testable pathway that connects treatment, efferocytosis, cytokine regulation, and behavior.

For neuropathic pain research, the broader implication is that restoration of apoptotic-cell clearance may help interrupt the feedback loop between cell death and inflammation. This does not establish ozone as a clinical treatment, but it identifies macrophage efferocytosis and the Gas6–MerTK pathway as experimentally tractable points for further investigation.

Comparison with Existing Internal Articles

The internal article Ozone Enhances Macrophage Efferocytosis to Alleviate Neuropathic Pain provides a concise overview of the same central interpretation: ozone may reduce neuropathic pain by promoting apoptotic-cell clearance through AMPK/Gas6–MerTK/SOCS3 signaling. Its value is as a thematic summary, whereas the present analysis emphasizes how the CCI model, BMDM phagocytosis assay, cytokine measurements, and inhibitor experiments support that interpretation.

The related resource Ozone Enhances Macrophage Efferocytosis to Relieve Neuropathic Pain similarly highlights neuroinflammation and efferocytosis as therapeutic concepts. Compared with that broader framing, the reference study adds an important distinction between Gas6 and Protein S and provides a more explicit pharmacological test of AMPK and MerTK involvement. Neither internal overview should replace the primary article when reproducing experimental details.

Limitations and Transferability

Several limitations affect how far these findings can be generalized. First, the evidence comes from a mouse CCI model and from BMDMs exposed to ozone in vitro. CCI captures important features of nerve-injury pain, but it does not represent all neuropathic pain etiologies, including diabetic neuropathy, chemotherapy-induced neuropathy, or central nervous system lesions. Macrophages derived from bone marrow also do not fully reproduce the phenotypes of tissue-resident macrophages or macrophages located at injured nerves.

Second, compound C and UNC2541 provide useful pathway interrogation but are not definitive genetic validation. Complementary approaches, such as macrophage-specific pathway manipulation or MerTK loss-of-function models, would help establish cell-type specificity and reduce uncertainty about pharmacological selectivity. The study also supports association between enhanced efferocytosis, SOCS3 induction, and cytokine suppression, but the precise temporal order and relative contribution of each event require additional experiments.

Third, the effective ozone condition was defined within the authors' experimental system. Dose, delivery method, exposure kinetics, tissue distribution, and safety cannot be transferred directly from mice to humans. The findings should therefore be viewed as mechanistic preclinical evidence, not as proof of clinical efficacy. Future studies should test additional pain models, assess durability of behavioral improvement, characterize macrophage states in injured tissues, and determine whether efferocytosis enhancement remains beneficial when inflammation is driven by different causes.

Why this cross-domain matters, maturity, and limitations

Macrophage efferocytosis and extracellular pH measurement belong to different experimental domains, but pH can be a useful complementary variable in studies of inflammation, metabolism, ion transport, and tissue microenvironments. A carefully designed pH readout could help characterize whether an intervention changes the extracellular conditions surrounding immune cells. However, the reference study did not report that ozone altered extracellular pH, and its data do not establish pH as a mediator of AMPK/Gas6–MerTK/SOCS3 signaling.

Accordingly, adding pH measurements would be hypothesis-generating rather than a validated extension of the paper. Researchers should distinguish extracellular or accessible-compartment pH from intracellular signaling and avoid treating a fluorescence change as direct evidence of efferocytosis. This cross-domain application is therefore mature as an assay concept but preliminary as a mechanistic connection to the reported neuropathic pain pathway.

Research Support Resources

For experiments that add extracellular acid–base characterization to macrophage, ion-transport, or inflammatory workflows, researchers can use BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein), SKU C5694. This membrane-impermeant, dual-excitation ratiometric pH fluorescent dye is described for extracellular or accessible-compartment measurements; its reported pH response uses the emission ratio at 535 nm after excitation at 490 nm versus 440 nm, with a pKa of approximately 6.98. It can serve as a fluorescent pH probe for ion transport studies, a probe for cellular metabolism pH monitoring, or a supporting readout in a microenvironmental pH regulation assay and acid-base homeostasis research tool. BCECF was not used in the reference study and should be treated as a complementary analytical tool, not as evidence for the ozone mechanism.